The stock is one of the cheapest high-growth stocks around.Shares of Hims & Hers Health (HIMS -4.88%) jumped following the company's first-quarter earnings report that once again announced surging revenue growth. That performance has helped the stock perform well this year, up about 40%.Let's look at some recent comments from the CEO that caused the stock to dip, the company's recent quarterly results, and whether it's too late to buy the stock.Controversial comments sink stock ahead of earningsHims & Hers ...

Prostock-Studio/iStock via Getty ImagesIntroduction It's been a wild few days for Hims & Hers (NYSE:HIMS) stock. Last Friday, CEO Andrew Dudum posted several controversial tweets on X, one of which included his support for university students to protest "against the genocide of the Palestinian people & for your university's divestment from Israel". This sparked a lot of rage and panic among the investing community, sending HIMS stock 8% lower in a single trading day. Even Shark Tank Co-host Kevin O'Lear ...

Hims & Hers Health, Inc. (HIMS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following yea ...

Strong earnings have sent this healthcare company higher today.Shares of growth stock Hims & Hers Health (HIMS 7.38%) jumped as much as 17.1% in trading on Tuesday after the company reported first-quarter 2024 financial results. As of 3 p.m. ET, shares were holding about an 8.4% gain for the day.Crushing expectationsHims & Hers said revenue for the quarter jumped 46% from a year ago to $278.2 million and sailed past the $268.7 million that analysts were expecting. The company also reported net income of $11 ...

Key PointsShares of Hims & Hers stock rallied double after announcing the company's first quarter 2024 results. Investors now have additional evidence to support a bullish company thesis that could run for the next decade.Bullish EPS projections and price targets suggest the stock still needs to be done rallying.5 stocks we like better than Technology Select Sector SPDR FundShares of Hims & Hers Health Inc. NYSE: HIMS are jumping by as much as 15.5% after the company released its first quarter 2024 earnings ...

Hims & Hers Health, Inc. (NYSE:HIMS) Q1 2024 Earnings Conference Call May 6, 2024 5:00 PM ET Company Participants Bill Newby - Head, IR Andrew Dudum - Co-Founder and CEO Yemi Okupe - CFO Conference Call Participants Allen Lutz - Bank of America Maria Ripps - Canaccord Daniel Grosslight - Citi Jack Wallace - Guggenheim Securities Jonna Kim - TD Cowen Aaron Kessler - Seaport Global Glen Santangelo - Jefferies Jailendra Singh - Truist Securities Korinne Wolfmeyer - Piper Sandler George Hill - Deutsche Bank Ope ...

Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 150%. A quarter ago, it was expected that this company would post a loss of $0.02 per share when it actually produced earnings of $0.01, delivering a surprise of 150%.Over the last four quarters, the company h ...

Financial Performance - Revenue for Q1 2024 was $278,171,000, a 46% increase from $190,770,000 in Q1 2023[20] - Gross profit for Q1 2024 was $229,095,000, compared to $153,425,000 in Q1 2023, reflecting a 49% increase[20] - Net income for Q1 2024 was $11,128,000, a significant improvement from a net loss of $10,067,000 in Q1 2023[20] - Adjusted EBITDA for the three months ended March 31, 2024, was $32,347,000, compared to $6,060,000 in the same period of 2023, indicating a significant improvement in operational performance[136] - Free Cash Flow for the three months ended March 31, 2024, was $11,880,000, up from $6,973,000 in the same period of 2023, reflecting enhanced liquidity[138] - Adjusted EBITDA margin for the three months ended March 31, 2024, was 12%, compared to 3% in the same period of 2023, indicating improved profitability[136] - Net income for the three months ended March 31, 2024, was $11.1 million, compared to a net loss of $10.1 million in the same period of 2023[153] Revenue Breakdown - Online revenue reached $267.761 million, up 45% from $184.175 million year-over-year[42] - Wholesale revenue increased to $10.410 million, a 58% rise compared to $6.595 million in the prior year[42] - Total revenue for the three months ended March 31, 2024, was $278.2 million, reflecting an increase of $87.4 million, or 46%, from $190.8 million in 2023[121] - For the three months ended March 31, 2024, the Company generated $267.8 million in Online Revenue, an increase of $83.6 million, or 45%, compared to $184.2 million for the same period in 2023[121] - Wholesale Revenue for the same period was $10.4 million, up $3.8 million, or 58%, from $6.6 million in the prior year[122] Assets and Liabilities - Total current assets decreased slightly to $261,734,000 as of March 31, 2024, from $265,053,000 at the end of 2023[18] - Total assets increased to $448,106,000 as of March 31, 2024, up from $441,186,000 at the end of 2023[18] - Total liabilities rose to $103,624,000 as of March 31, 2024, compared to $97,157,000 at the end of 2023[18] - Cash and cash equivalents increased to $105,237,000 as of March 31, 2024, from $96,663,000 at the end of 2023[18] - Short-term investments as of March 31, 2024, totaled $98.355 million, a decrease from $124.318 million at the end of 2023[53] Operating Expenses - Operating expenses for Q1 2024 totaled $219,192,000, up from $164,688,000 in Q1 2023, representing a 33% increase[20] - Marketing expenses rose to $130.6 million, a 34% increase from $97.2 million in the same period last year, driven by higher customer acquisition costs of $113.2 million[157] - Operations and support expenses increased by 48% to $38.7 million, primarily due to higher employee compensation and order fulfillment costs[158] - Technology and development expenses were $15.3 million, up 43% from $10.7 million, mainly due to increased employee compensation and technology costs[159] - General and administrative expenses increased to $34.6 million, a 13% rise from $30.5 million, largely due to higher stock-based compensation and professional services[160] Cash Flow - Cash provided by operating activities for Q1 2024 was $25,838,000, compared to $9,483,000 in Q1 2023[26] - Net cash provided by operating activities was $25.8 million for the three months ended March 31, 2024, compared to $9.5 million in the same period of 2023[166] - Net cash used in investing activities for Q1 2023 was $4.1 million, primarily due to $1.9 million in website development and internal-use software[172] - Net cash used in financing activities for Q1 2024 was $30.3 million, mainly from Class A common stock repurchases of $28.1 million and tax payments of $7.3 million[173] Stock and Compensation - The company repurchased 2,023,080 shares of Class A common stock for $28.1 million during the three months ended March 31, 2024, leaving $19.9 million available under the share repurchase program[75] - The total stock-based compensation expense for the three months ended March 31, 2024, was $19.0 million, an increase from $14.2 million in the same period of 2023, reflecting a 34% year-over-year growth[101] - As of March 31, 2024, there was $194.7 million of unrecognized stock-based compensation expense related to unvested RSUs, expected to be recognized over a weighted average period of 3.36 years[92] - The intrinsic value of vested options exercised as of March 31, 2024, was $7.4 million, with 1,531,019 stock options exercised at a weighted average exercise price of $2.43[85] Subscriber Growth and Metrics - Subscribers grew by 41% to approximately 1.7 million as of March 31, 2024, compared to approximately 1.2 million a year earlier[123] - Monthly Online Revenue per Average Subscriber remained stable at $55 for both the three months ended March 31, 2024, and 2023[123] - Net Orders increased by 20% to approximately 2.5 million for the three months ended March 31, 2024, compared to approximately 2.0 million in the same period of 2023[124] - Average Order Value (AOV) rose by 21% to $109 for the three months ended March 31, 2024, up from $90 in the prior year[124] Market and Operational Challenges - The company has faced risks related to its limited operating history and evolving business model, which complicates future growth evaluations[194] - The company must expand its offerings, including products and services, to maintain financial health and operational success[195] - The company relies on attracting and retaining customers for revenue generation, which is critical for its financial condition[197] - The healthcare industry is undergoing significant structural changes, impacting demand for the company's technology-driven services and subscription business model[215] - The effectiveness of the company's digital marketing is at risk due to potential changes in regulations and third-party practices that limit data collection and targeted advertising[199] Future Outlook - The company expects to continue investing in fulfillment and operating capabilities, including expansion of facilities over the next 12 months[130] - Marketing expenses are anticipated to increase as the company continues to invest in customer acquisition, with a historical trend of quarter-over-quarter growth[147] - The company aims to expand into new health and wellness specialties, which will require financial investments in headcount and marketing[131] - The company plans to continue investing in marketing and may repurchase up to $19.9 million of its Class A common stock through the fourth quarter of 2025[165]

Hims & Hers Health, Inc. Reports First Quarter 2024 Financial Results Revenue of $278.2 million, up 46% year-over-year in 2024 Net income of $11.1 million; Adjusted EBITDA of $32.3 million in Q1 2024 Subscribers grew to 1.7 million, up 41% year-over-year in Q1 2024 Raises full year 2024 guidance to a range of $1.20 billion to $1.23 billion and Adjusted EBITDA to a range of $120 million to $135 million SAN FRANCISCO, May 6, 2024 – Hims & Hers Health, Inc. ("Hims & Hers" or the "Company", NYSE: HIMS), the lea ...

Hims & Hers founder and CEO Andrew Dudum said Sunday that his previous comments offering support for anti-Israel protesters on college campuses were "misconstrued by some" after the company's stock dipped. In a thread on X, Dudum said he wished to clarify his earlier comments and said he does not support violence, antisemitism or intimidation."The last few days have been a disheartening reflection of just how divisive a time we live in," Dudum began. "I'd like to clarify a few things because my words have b ...